WO2006090836A1 - 電離放射線の被曝量測定方法 - Google Patents
電離放射線の被曝量測定方法 Download PDFInfo
- Publication number
- WO2006090836A1 WO2006090836A1 PCT/JP2006/303415 JP2006303415W WO2006090836A1 WO 2006090836 A1 WO2006090836 A1 WO 2006090836A1 JP 2006303415 W JP2006303415 W JP 2006303415W WO 2006090836 A1 WO2006090836 A1 WO 2006090836A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- type
- protein
- ionizing radiation
- lygdi
- tissue
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96466—Cysteine endopeptidases (3.4.22)
Definitions
- the present invention relates to a method for measuring the exposure dose of ionizing radiation, which makes it possible to directly know the biological effects of ionizing radiation applied to a living body by utilizing a biochemical reaction. Related.
- thermoluminescence dosimeters To measure the exposure dose of ionizing radiation, it is common to use physical reactions caused by ionizing radiation. Specifically, film batches, thermoluminescence dosimeters, pocket dosimeters, etc. are used. (Practical revision of radiation management for the chief of the Japan Isotope Association Rev. 2 1992 pl40).
- the film batch is a case in which a photographic emulsion-coated resin film is housed in a case, and the black emulsion is shown in proportion to the radiation dose to which the photographic emulsion is exposed along with the photosensitive action.
- a thermoluminescence dosimeter is a dosimeter that utilizes luminescence (fluorescence) generated when a crystalline substance irradiated with radiation is heated, and is an electron that is separated in the crystal by irradiation with electron radiation.
- the dose of ionizing radiation is measured using the principle that holes are emitted when holes recombine by thermal stimulation.
- the pocket dosimeter measures the exposure dose of ionizing radiation from the current value that flows when the gas sealed in the ionization chamber ionizes according to the radiation dose.
- the physical measurement method measures the dose of the irradiated ionizing radiation as a dose absorbed by various measuring devices.
- the surface of the living body is irradiated. Therefore, the dose of radiation that has reached the inside of the living body cannot be measured. For example, when exposed to 32 P gamma rays, which are less transmissive, the film badge will react, but much of the radiation will be weakened by clothing or other shielding. For this reason, the exposure dose measured by the above physical method does not necessarily accurately reflect the dose actually exposed to the living body.
- the physical measurement method described above has the power to accurately reflect the influence of radiation having different RBE (Radiation Biological Effectiveness) on the living body.
- RBE Room Biological Effectiveness
- neutron IGy and X-ray IGy are known to have a biological effect of neutrons that is twice to ten times that of X-rays.
- the method only displays the same 1 Gy.
- the physical method has a concept of “effective dose” for calibrating the difference in radiation quality, and is introduced by law.
- it is necessary to calculate the exposure dose after specifying the exposed radiation quality and tissue.
- the exposure dose for each tissue must be calculated using the “tissue weighting factor” for each organ, and the exposure dose must be expressed as the sum of the exposure dose for each tissue. .
- tissue weighting factor for each organ
- the exposure dose must be expressed as the sum of the exposure dose for each tissue.
- the effective dose obtained in this way can accurately indicate the effect on each individual! Met.
- An ionizing radiation exposure measuring method comprising:
- a kit for measuring the exposure dose of ionizing radiation, and immunoplot the expression level of at least one of LyGDI protein type 1 and type 3 caspase degradation products contained in tissue from which biological force was collected or blood force was also extracted A kit for measuring an exposure dose of ionizing radiation comprising an antibody for measurement by a method.
- apoptosis occurs by irradiation with ionizing radiation.
- This apoptosis involves the action of the tumor suppressor gene product p53, and the induction of apoptosis involves the involvement of a signal system via mitochondria and the activity of the downstream protease caspase group.
- the associated DNA-degrading enzymes are involved, and apoptosis may cause the cleavage of various molecules in the cell. Is known.
- a LyGDI protein (a molecule called GDI-D4, RhoGDI2, RhoGDI ⁇ , which is highly expressed in blood cells, Factors that inhibit the process by which GDP is released from G protein and become active) are known.
- the human LyGDI protein represented by SEQ ID NO: 1 is a type 3 cassette on the C-terminal side of the 19th aspartic acid (18th for the mouse LyGDI protein represented by SEQ ID NO: 2). It is known that there is a site that is cleaved by a space, and there is a site that is cleaved by type 1 caspase at the end of 55th aspartic acid (54th in mouse LyGDI protein).
- the present inventor has shown that the expression level of LyGDI protein type 1 and type 3 caspase degradation products varies with the dose of ionizing radiation, and the tissue And they found that their expression patterns differ depending on blood, and based on this, the present invention was completed.
- the influence of the exposed ionizing radiation force on the living body can be directly measured even if the measuring apparatus is not carried in advance.
- ionizing radiation can be absorbed into the living body even in the event of exposure due to nuclear material production accidents, nuclear power plant accidents, sudden nuclear material leaks such as nuclear weapons. It is possible to grasp the impact on the site more accurately.
- the exposure dose of ionizing radiation can be measured with higher accuracy than the conventional methods of measuring the number of white blood cells and the deformation force exposure dose. Furthermore, according to the present invention, a minute amount of exposure dose that cannot be grasped by a change in white blood cells can be measured by a blood test.
- FIG. 1 is a diagram schematically showing the structure of a human LyGDI protein.
- FIG. 2 is a diagram showing amino acid sequences of human LyGDI protein and mouse LyGDI protein, and cleavage sites by type 1 caspase and type 3 caspase.
- Fig. 3 shows the results of immunoplotting proteins from which thymus tissue strength of mice was also extracted.
- FIG. 4 schematically shows changes in the exposure dose of mouse thymus tissue and the expression level of type 1 or type 3 caspase degradation products.
- FIG. 5 shows the results of immunoplotting proteins from which bone marrow tissue strength of mice was also extracted.
- FIG. 6 shows the results of immunoplotting proteins extracted from spleen tissue strength of mice.
- FIG. 7 shows the results of immunoplotting proteins from which intestinal epithelial tissue strength of mice was also extracted.
- FIG. 8 shows the result of immunoplotting a protein from which blood force of a mouse was also extracted.
- FIG. 9 shows the result of immunoplotting a protein from which leukocyte strength in human peripheral blood is also extracted.
- FIG. 10 shows the result of immunoplotting a protein from which leukocyte strength in human peripheral blood was also extracted.
- the present invention is based on the fact that when a living body is exposed to ionizing radiation, the appearance pattern of degradation products due to type 1 and type 3 caspase of the LyGD I protein changes according to the exposure dose. It is characterized by measuring the dose of ionizing radiation.
- the method for measuring the exposure dose of ionizing radiation includes (a) extracting a protein from tissue or blood force collected from a living body, and (b) LyG DI protein contained in the extracted protein. Measuring the expression level of at least one of the type 1 and type 3 caspase degradation products. Therefore, details related to the following will be described in detail.
- the target for measuring the exposed ionizing radiation dose can be measured without limitation as long as it is a tissue and blood that constitutively expresses LyGDI protein.
- thymus tissue is preferred among thymus tissue, bone marrow tissue, spleen tissue, intestinal epithelial tissue or blood, but blood can be sufficiently measured.
- the blood contains peripheral blood containing thymic cells (T cells).
- T cells thymic cells
- examples of organisms from which these tissues or blood are collected include mammals such as mice, dogs, cats, pigs, and cattle. If blood is a body that can be collected from humans, tissues can be collected. May be collected from humans.
- Peripheral blood is preferable as the blood used in the method for measuring radiation exposure according to the present invention because peripheral blood can be easily collected.
- Collection of vital tissue or blood is a normal method, specifically a surgical method using a messenger for tissue, aspiration with a syringe for blood, and precipitation of blood cells with a centrifuge , Can be performed.
- Protein extraction is also performed by a normal method, specifically by suspending tissue or blood cells in a buffer solution and crushing the tissue or cells with a homogenizer or a French press. If necessary, denaturing agents, antioxidants, etc. may be added to the buffer solution, and nucleic acids such as DNA contained in the cell disruption solution and fats contained in the cell membrane may be removed.
- any method can be used as long as it can specifically measure the expression level of the protein to be expressed, but the method using antigen-antibody reaction, specifically, the immuno-plot method (Western blot) can be used. Method), ELISA method can be used.
- an anti-LyGDI antibody against LyGDI protein, an antibody against type 1 or type 3 caspase degradation product, and the like can be used.
- LyGDI protein and caspase degradation product will be described. An explanation will be given using LyGDI proteins derived from humans and mice as examples. The amino acid sequences of these proteins are represented by FIG.
- the type 3 caspase cleavage site of LyGDI protein is on the C-terminal side of 19th aspartic acid in humans, and on the C-terminal side of 18th aspartic acid in mice.
- the type 1 caspase cleavage site of LyGDI protein is located on the C-terminal side of 55th aspartic acid in the case of human, and on the C-terminal side of 54th aspartic acid in the case of mouse. Therefore, the amino acid sequence of the type 3 caspase degradation product of human LyGDI protein is represented by SEQ ID NO: 3, the amino acid sequence of the type 3 caspase degradation product of mouse LyGDI protein is represented by SEQ ID NO: 4, and 1 of human LyGDI protein.
- the amino acid sequence of the type caspase degradation product is represented by SEQ ID NO: 5
- the amino acid sequence of the mouse LyGDI protein type 1 caspase degradation product is represented by SEQ ID NO: 6.
- the type 1 or type 3 caspase degradation product has, for example, one or several amino acids deleted, substituted or added in the amino acid sequence represented by SEQ ID NOs: 3 to 6.
- a known immunoplot method can be used. Specifically, the protein is extracted using a buffer solution to which a denaturing agent such as sodium dodecyl sulfate (SDS) is added, and then polyatyramide gel electrophoresis is performed. After electrophoresis is complete, transfer the protein on the gel to a PVDF membrane or -trocellulose membrane and visualize it using anti-LyGDI protein antibody, etc. The expression level of is measured.
- a denaturing agent such as sodium dodecyl sulfate (SDS)
- SDS sodium dodecyl sulfate
- a known ELISA method can also be used when measuring the expression level of a type 1 or type 3 caspase degradation product by ELISA. Specifically, an anti-LyGDI protein antibody or the like is bound to a solid phase such as polystyrene, a protein extract is added thereto, and the enzyme-labeled antibody is reacted and visualized, whereby type 1 or Measure the expression level of type 3 caspase degradation product.
- the expression patterns of type 1 and type 3 caspase degradation products are different, so when exposure to a small amount of ionizing radiation, there are two indicators, namely LyGDI, to accurately measure the exposure dose. It is preferable to measure the expression level of both type 1 caspase degradation products and type 3 caspase degradation products.
- the expression level of full-length LyGDI U prefer to measure.
- the full-length LyGDI is, for example, an amino acid sequence having one, several amino acids deleted, substituted or added in the amino acid sequence represented by SEQ ID NO: 1 or 2, and Contains proteins that include sites cut by type 1 or type 3 caspase.
- the dose of ionizing radiation can be measured by the following method. First, the change in the expression level of type 1 or type 3 caspase degradation product with respect to the dose of ionizing radiation as shown in FIG. Create a schematic diagram of Then, the expression level of type 1 or type 3 caspase degradation product contained in tissue or blood collected from the vital force is measured by Western blotting or the like, and the exposure dose of ionizing radiation is measured from the schematic diagram.
- the expression level of the type 1 or type 3 caspase degradation product in the extracted protein when not exposed to ionizing radiation and after exposure.
- the amount of type 1 or type 3 caspase degradation product at the time of non-ionizing radiation exposure cannot be measured. It is possible to suspect exposure to ionizing radiation simply by measuring the expression level.
- the ionizing radiation exposure measurement kit of the present invention includes an antibody for measuring the expression level of at least one of LyGDI protein type 1 and type 3 caspase degradation products by immunoplotting.
- the antibody is not particularly limited as long as it is used for immunoplot and is an antibody against at least one of type 1 and type 3 caspase degradation products of LyGDI protein.
- a 7-week-old male mouse (C57BLZ6NCrj (trade name), Charles River Japan) was bred in a normal environment until 8-9 weeks of age, and then an X-ray generator (Shin-ai No. (trade name, manufactured by Shimadzu Corporation) ), 200 kVp, 25 mA), and the whole body was irradiated with X-rays (ionizing radiation) at an irradiation dose rate of 0.6 Gy.
- the irradiation amount exposure amount was adjusted according to the irradiation time.
- mice were dissected to collect thymus tissue, and the collected tissue was minced with a scalpel and solubilized in SDS-sample buffer to obtain a solubilized sample.
- the composition of SDS-sample buffer is 5% glycerol, 25 mM TrisHCl (pH 6.8), 1% SDS.
- Electrophoresis Prepare a 12% polyacrylamide gel (separation gel), overlay 4% polyacrylamide gel (concentrated gel) on it, and apply the above soluble sample to 20 g per lane. Electrophoresis (electrophoretic conditions are as follows. The electrophoretic current in the concentrated gel was 20 mA, the electrophoretic current in the separation gel was 40 mA, and Tris-glycine buffer was used as the running buffer;)). After the electrophoresis was completed, the concentrated gel was cut off, and the separated gel was equilibrated (twice) for 5 minutes with a transfer buffer.
- the separation gel was 3 mL of 40% acrylamide stock solution: Lower gel buffer (1.5 M TrisHCl (pH 8.8), 0.4% SDS) 2.5 mL sterilized milli-Q water 4.5 mL, 10 % Ammonium persulfate aqueous solution 50 L, N, N, ⁇ , N, -Tetramethylethylenediamine 10 L was mixed.
- Lower gel buffer 1.5 M TrisHCl (pH 8.8), 0.4% SDS
- the concentrated gel is composed of 0.5 mL of 40% acrylamide stock solution, Upper gel buffer.
- Tris-glycine buffer is 25 mM Tris, 192 mM glycine, 0.1%
- the composition of the transfer buffer is 25 mM Tris, 192 mM glycine, 10% methanol.
- the equilibrated gel was transferred to a polyvinylidene difluoride membrane (PVDF: Nippon Aidichi Co., Ltd.) in a transfer buffer by a semi-dry method (100 mA, 3 hours). After the transfer, the PVDF membrane was blocked with PBST containing 5% skim milk for 1 hour.
- PVDF polyvinylidene difluoride membrane
- a LyGDI protein C-terminal recognition antibody (manufactured by Santa Cruz, Power Tag No. Sc-604) was bound for 1 hour and washed twice with PBST for 5 minutes.
- alkaline phosphatase-labeled anti-mouse IgG H + L
- Fig. 3 The results are shown in Fig. 3.
- Fig. 3 (a) the type 1 caspase degradation product (17 kDa) disappeared once in the low exposure dose range ( ⁇ 0.1 Gy), but reappeared at 0.5 Gy or more.
- the type 3 caspase degradation product (21 kDa) was prominently expressed when the whole-body irradiation dose exceeded 5 Gy.
- Fig. 3 (b) a decrease in the expression of type 1 caspase degradation product (17 kDa) was observed even at a dose as low as 4 mGy.
- FIG. 4 schematically shows the change in the expression level of the type 1 or type 3 caspase degradation product with respect to the exposure dose. As is clear from this figure, there is a certain relationship between the exposure dose and the expression pattern of type 1 and type 3 caspase degradation products. The amount of ionizing radiation that was exposed to can be estimated.
- the 21 kDa band on the film is a degradation product of type 3 caspase, indicating that an antibody that recognizes the type 3 caspase cleavage point (an antibody that recognizes the N-terminal side of the long chain after cleavage, KLH Confirmation was performed by immunoplotting the same PVDF membrane using a non-specific antibody: a monoclonal antibody with the amino acid sequence SKLNYKPPPQKC (SEQ ID NO: 7) as an antigen (data not shown). By immunoplotting with LyGDI protein N-terminal recognition antibody (Phamingen, catalog No. 66456E), N-terminal fragments that appear to have been cleaved at each caspase may also appear. Confirmed (data not shown) o Based on these information, it was confirmed that the 17 kDa band caspase degradation product and the 21 kDa band were the type 3 caspase degradation product.
- Fig. 7 As shown in this figure, intestinal epithelial tissue constantly produced a type 3 caspase degradation product (21 kDa) in a non-irradiated state (OGy). On the other hand, expression of full-length LyGDI protein was not observed above 5 Gy, and type 3 caspase degradation product was not observed above 12 Gy. In addition, type 1 caspase degradation product was almost unexpressed. This is said to be due to the fact that small intestinal epithelial cells fall off due to irradiation.
- the expression patterns of type 1 and type 3 degradation products change depending on the dose of ionizing radiation in tissues and blood collected from mouse force, and vice versa. For example, it was confirmed that the exposure dose of ionizing radiation could be measured by examining the expression patterns of type 1 and type 3 degradation products.
- a subject (adult male, 49 years old) performed a normal panoramic shot once on his jaw (radiation dose) using a dental panoramic X-ray apparatus (trade name: auto lOOOOex, manufactured by Asahi Roentgen). : About 20mGy).
- a lead apron was worn at the time of photography.
- Blood peripheral blood was collected before X-ray irradiation and 6 hours after irradiation, and after separating leukocytes, it was dissolved in SDS-sample buffer and the amount of protein was quantified.
- Antibody l sc—6047G (trade name, manufactured by SantaCruz, goat polyclonal antibody with LyGDI C-terminal region as epitope)
- Antibody 2 66586E (trade name, manufactured by Pharmingen, full-length LyGDI is used as an antigen, and is epitope-mapped, rabbit antibody polyclonal antibody)
- Antibody 3 71-6300 (Brand name, 2 1! 1 ⁇ 2 (manufactured by Usagi Polyclonal Antibody with Epitope at the center of LyGDI)
- Antibody 4 97A1015 (trade name, manufactured by Active Motif, mouse monoclonal antibody that recognizes the N-terminus of ⁇ 19—LyGDI)
- Subject (cancer patient, adult male, 67 years old) was irradiated with ionizing radiation to the abdomen using a linac irradiation device for cancer treatment (trade name: Mevatron 67-6300, manufactured by Siemens) (radiation dose: approx. 2Gy).
- linac irradiation device for cancer treatment trade name: Mevatron 67-6300, manufactured by Siemens
- Blood peripheral blood was collected before irradiation and 6 hours after irradiation, and after separating white blood cells, it was dissolved in SDS sample buffer and the amount of protein was quantified.
- Antibody 1 sc—6047G (trade name, manufactured by SantaCruz)
- Antibody 2: 66586E (trade name, manufactured by Pharmingen)
- Antibody 4 97A1015 (trade name, manufactured by Active Motif)
- the influence of the exposed ionizing radiation force on the living body can be directly measured without carrying a measurement device in advance.
- ionizing radiation is given to living bodies even in the event of exposure due to nuclear material production accidents, nuclear power plant accidents, sudden nuclear material leaks such as nuclear weapons. The impact can be grasped more accurately.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of Radiation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/884,945 US20080283763A1 (en) | 2005-02-25 | 2006-02-24 | Method of Measuring Exposed Dose of Ionizing Radiation |
AU2006216188A AU2006216188A1 (en) | 2005-02-25 | 2006-02-24 | Method of measuring exposure dosage of ionizing radiation |
EP06714554A EP1857819A4 (en) | 2005-02-25 | 2006-02-24 | METHOD OF MEASURING CONTACT DOSE IONIZING RADIATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-050497 | 2005-02-25 | ||
JP2005050497 | 2005-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006090836A1 true WO2006090836A1 (ja) | 2006-08-31 |
Family
ID=36927469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/303415 WO2006090836A1 (ja) | 2005-02-25 | 2006-02-24 | 電離放射線の被曝量測定方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080283763A1 (ja) |
EP (1) | EP1857819A4 (ja) |
CN (1) | CN101184998A (ja) |
AU (1) | AU2006216188A1 (ja) |
RU (1) | RU2007135360A (ja) |
WO (1) | WO2006090836A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105807061A (zh) * | 2014-12-29 | 2016-07-27 | 中国辐射防护研究院 | 电离辐射生物标记的筛选方法及由此确定的b8x1j0、upf1蛋白的用途 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101661017B (zh) * | 2009-09-22 | 2011-02-16 | 湖南科技大学 | 一种用于铀污染检测的美洲商陆铀诱导下差异表达的标准蛋白斑点质谱图的获取方法及运用 |
CN101975964A (zh) * | 2010-08-23 | 2011-02-16 | 苏州大学 | 高迁移率族蛋白b1作为电离辐射生物剂量计的应用 |
CN107090496A (zh) * | 2017-03-28 | 2017-08-25 | 南方医科大学 | 一种8Gy电离辐射的检测方法 |
CN117130035A (zh) * | 2017-08-18 | 2023-11-28 | 南京中硼联康医疗科技有限公司 | 生物剂量计及具有其的中子捕获治疗系统 |
-
2006
- 2006-02-24 WO PCT/JP2006/303415 patent/WO2006090836A1/ja active Application Filing
- 2006-02-24 AU AU2006216188A patent/AU2006216188A1/en not_active Abandoned
- 2006-02-24 RU RU2007135360/15A patent/RU2007135360A/ru not_active Application Discontinuation
- 2006-02-24 EP EP06714554A patent/EP1857819A4/en not_active Withdrawn
- 2006-02-24 CN CNA2006800139200A patent/CN101184998A/zh active Pending
- 2006-02-24 US US11/884,945 patent/US20080283763A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
FUKUDA E. ET AL.: "Jurkat Saibo o Mochiita Hoshasen Otosei Tanpakushitsu no Morateki Kaiseki (Proteome analysis of cellular responses to radiation in Jurkat cells)", NAGASAKI MEDICINAL JOURNAL, TOKUSHUGO, vol. 79, 2004, pages 263 - 266, XP003000016 * |
See also references of EP1857819A4 * |
XINWENG ZHOU: "Nuclear Translocation of Cleaved LyGDI Dissociated from Rho and Rac during Trp53-Depencent Ionizing Radiation-Induced Apoptosis of Thymus Cells In Vitro", RADIATION RESEARCH, vol. 162, September 2004 (2004-09-01), pages 287 - 295, XP003000015 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105807061A (zh) * | 2014-12-29 | 2016-07-27 | 中国辐射防护研究院 | 电离辐射生物标记的筛选方法及由此确定的b8x1j0、upf1蛋白的用途 |
CN105807061B (zh) * | 2014-12-29 | 2018-08-21 | 中国辐射防护研究院 | 电离辐射生物标记的筛选方法及由此确定的b8x1j0、upf1蛋白的用途 |
Also Published As
Publication number | Publication date |
---|---|
EP1857819A1 (en) | 2007-11-21 |
EP1857819A4 (en) | 2008-07-23 |
RU2007135360A (ru) | 2009-03-27 |
AU2006216188A1 (en) | 2006-08-31 |
CN101184998A (zh) | 2008-05-21 |
US20080283763A1 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60028040T2 (de) | Annexin-proteine und auto-antikörper als serummarker für lungenkrebs und ösophaguskrebs | |
RU2161042C2 (ru) | Обнаружение и лечение рака | |
WO2003089904A2 (en) | Aib1 as a prognostic marker and predictor of resistance to encocrine therapy | |
JPH05509308A (ja) | がん関連scm認織因子、その生成法および使用法 | |
WO2006090836A1 (ja) | 電離放射線の被曝量測定方法 | |
JP2023529026A (ja) | Mhc-i発現を調節するための方法及びその免疫療法の使用 | |
KR20120057562A (ko) | 피브린 및 피브리노겐 분해 생성물의 검출 및 관련된 제조 방법 및 암의 검출 및 모니터링을 위한 용도 | |
CN103648585A (zh) | 基于多肽辐射毒性血清标记的处置规划 | |
KR20120049758A (ko) | Clic1을 측정하는 제제를 포함하는 방사선 저항성 또는 민감성 진단용 조성물 및 이의 용도 | |
ES2534330T3 (es) | Método de análisis biológico para anticuerpo contra el receptor de la hormona estimuladora tiroidea, kit de medición para el anticuerpo, y célula modificada genéticamente novedosa para su uso en el método de análisis biológico o en el kit de medición | |
Huang et al. | Serum amyloid A1 as a biomarker for radiation dose estimation and lethality prediction in irradiated mouse | |
JP4853866B2 (ja) | 電離放射線の被曝量測定方法 | |
Bensimon Etzol et al. | DosiKit, a new immunoassay for fast radiation biodosimetry of hair and blood samples | |
CN115028713A (zh) | 一种抗冠状病毒n蛋白的抗体及其应用 | |
CN1215406A (zh) | 检测程序性细胞凋亡抗原的单克隆抗体 | |
CN110890133B (zh) | 急性反应期蛋白saa1在构建电离辐射后致死性预测模型或制备试剂盒、试剂的应用方法 | |
KR101270761B1 (ko) | 방사선 피폭 진단용 마커 트랜스알돌라아제, 그 마커의 발현수준을 측정하는 방사선 피폭 진단용 조성물, 그 조성물을 포함하는 방사선 피폭 진단용 키트, 및 그 마커를 이용한 방사선 피폭을 진단하는 방법 | |
RU2408284C2 (ru) | Способ прогнозирования исходов предоперационной лучевой терапии плоскоклеточных карцином головы и шеи | |
KR101776922B1 (ko) | 저선량 방사선 노출에 대한 특이 반응 지표로서 다클론 Ikaros (serine 391/393) 인산화 항체 개발 및 이의 용도 | |
RU2548783C1 (ru) | Способ дооперационного определения объема хирургического лечения высокодифференцированного рака щитовидной железы | |
KR101232228B1 (ko) | 방사선 피폭 진단용 마커 포스포글리세레이트 키나제, 그 마커의 발현수준을 측정하는 방사선 피폭 진단용 조성물, 그 조성물을 포함하는 방사선 피폭 진단용 키트, 및 그 마커를 이용한 방사선 피폭을 진단하는 방법 | |
Ahn et al. | Development of LGI1 antibody encephalitis after treatment of lung cancer | |
JP7227589B2 (ja) | 疾患の発症に関する診断のための情報を提供する方法 | |
US20230016321A1 (en) | Uses and applications in cancer and other proliferative condi-tions of oncoprotein csp80 and agents interacting with oncoprotein csp80 | |
CN107515305A (zh) | 宫颈癌标志物ebp50及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680013920.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006216188 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006714554 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006216188 Country of ref document: AU Date of ref document: 20060224 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006216188 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007135360 Country of ref document: RU Ref document number: 4259/CHENP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11884945 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2006714554 Country of ref document: EP |